Imperial is participating in a read and publish agreement with the Future Science Group's 20 hybrid and 15 Open Access journals, including read access and unlimited open access publishing for all articles. Future Science Group publishes 35 STM journals across three imprints: Future Medicine Ltd, Future Science Ltd and Newlands Press Ltd. Journals cover basic and clinical areas of biomedicine, and the portfolio includes titles such as BioTechniques, Future Oncology, Nanomedicine, Epigenomics, Immunotherapy, Bioanalysis, and Regenerative Medicine.
Journals included in this agreement and others we have signed can be found using our journal search tool using journal title, ISSN or keyword.
Under the terms of the agreement, eligible articles will be published under a CC-BY open access licence at no cost to the author.
To be eligible, articles must have a corresponding author whose primary affiliation is Imperial College London. The agreement does not apply to Drug Evaluation article types, Plain Language Summary of Publication articles or articles sponsored or funded by pharma/biotech.
If you have any questions regarding this agreement or the process please contact the open access team.